{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:53:23Z","timestamp":1778291603219,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting. A retrospective case series of patients that received IVT-B with a minimum of two injections performed and at least 4\u00a0weeks of follow-up after last injection. Nineteen eyes of 19 patients were included. The number of IVT-B performed for the whole cohort was 58 injections; the mean number of IVT-B per patient was 3.0 \u00b1 1.0 (range 2\u20136); the mean follow-up time was 14.4 \u00b1 9.0\u00a0weeks. Mean baseline best-corrected visual acuity was 0.4 \u00b1 0.4 logMAR and at the last follow-up was 0.4 \u00b1 0.6 logMAR (<jats:italic>p<\/jats:italic> = 0.778). All eyes showed a reduction in retinal thickness, with the central macular thickness being 470 \u00b1 151\u00a0\u03bcm at baseline and 360 \u00b1 144\u00a0\u03bcm at the last follow-up (<jats:italic>p<\/jats:italic> = 0.001). Intra-retinal fluid was present at baseline in 12 eyes (63%) and in three eyes (16%) at the last follow-up (<jats:italic>p<\/jats:italic> = 0.065). Sub-retinal fluid was present at baseline in 17 eyes (89%) and at the last follow-up in three eyes (16%, <jats:italic>p<\/jats:italic> = 0.011). Pigment epithelium detachment was apparent in the 16 eyes (84%) at baseline and was still present in 14 eyes (73%, <jats:italic>p<\/jats:italic> = 0.811). One adverse event of intraocular inflammation was reported. In conclusion, our short-term experience showed that brolucizumab was highly effective in restoring the anatomy and in stabilizing the visual acuity of eyes with nAMD. Its safety profile should be evaluated carefully and needs further investigations.<\/jats:p>","DOI":"10.3389\/fphar.2021.720345","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T09:00:59Z","timestamp":1636016459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice"],"prefix":"10.3389","volume":"12","author":[{"given":"Andrea","family":"Montesel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Bucolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferenc B.","family":"Sallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/IMCRJ.S252260","article-title":"Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration","volume":"13","author":"Avaylon","year":"2020","journal-title":"Int. Med. Case Rep. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S2468","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, And\/or Vascular Occlusion after Brolucizumab Treatment","volume":"5","author":"Baumal","year":"","journal-title":"Ophthalmol. Retina"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"B4","unstructured":"2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2020-318672","article-title":"Short-Term Real-World Outcomes Following Intravitreal Brolucizumab for Neovascular AMD: SHIFT Study","author":"Bulirsch","year":"2021","journal-title":"Br. J. Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0928-0987(97)00023-7","article-title":"Biodegradable Microspheres for the Intravitreal Administration of Acyclovir: In Vitro\/In Vivo Evaluation","volume":"5","author":"Conti","year":"1997","journal-title":"Eur. J. Pharm. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","article-title":"Early Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration","volume":"139","author":"Enr\u00edquez","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","article-title":"Associations of Variation in Retinal Thickness with Visual Acuity and Anatomic Outcomes in Eyes with Neovascular Age-Related Macular Degeneration Lesions Treated with Anti-Vascular Endothelial Growth Factor Agents","volume":"138","author":"Evans","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of Geographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-And-Extend Regimen: FLUID Study 24-Month Results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/jcm10122666","article-title":"Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes","volume":"10","author":"Haensli","year":"2021","journal-title":"J. Clin. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamaophthalmol.2020.2810","article-title":"Retinal Vasculitis after Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity","volume":"138","author":"Kondapalli","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"CD012208","DOI":"10.1002\/14651858.CD012208.pub2","article-title":"Treatment Regimens for Administration of Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s00417-021-05136-w","article-title":"Brolucizumab-Related Intraocular Inflammation in Japanese Patients with Age-Related Macular Degeneration: A Short-Term Multicenter Study","volume":"259","author":"Maruko","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s0161-6420(85)34001-0","article-title":"Standardization of Vitreal Inflammatory Activity in Intermediate and Posterior Uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2015.09.031","article-title":"Geo Epidemiology of Age-Related Macular Degeneration: New Clues into the Pathogenesis","volume":"161","author":"Reibaldi","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms21218242","article-title":"Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches","volume":"21","author":"Ricci","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1016\/j.ajo.2020.06.034","article-title":"Reply to Letter from Novartis on \"Is This a 737 Max Moment for Brolucizumab?\"","volume":"216","author":"Rosenfeld","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/eye.2017.67","article-title":"A Systematic Review to Assess the 'Treat-And-Extend' Dosing Regimen for Neovascular Age-Related Macular Degeneration Using Ranibizumab","volume":"31","author":"Rufai","year":"2017","journal-title":"Eye (Lond)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the Management of Neovascular Age-Related Macular Degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/bjophthalmol-2020-317528","article-title":"Brolucizumab: The Road Ahead","volume":"104","author":"Sharma","year":"","journal-title":"Br. J. Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","article-title":"Brolucizumab-Early Real-World Experience: BREW Study","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye (Lond)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41433-020-0853-9","article-title":"Brolucizumab and Immunogenicity","volume":"34","author":"Sharma","year":"","journal-title":"Eye (Lond)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41433-020-0831-2","article-title":"Brolucizumab and Fluid in Neovascular Age-Related Macular Degeneration (N-AMD)","volume":"34","author":"Sharma","year":"","journal-title":"Eye (Lond)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41433-020-0842-z","article-title":"Brolucizumab-Key Learnings from HAWK and HARRIER","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1038\/s41598-020-64901-9","article-title":"Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-Related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors","volume":"10","author":"Siedlecki","year":"2020","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"CD005139","DOI":"10.1002\/14651858.CD005139.pub4","article-title":"Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.720345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T09:01:01Z","timestamp":1636016461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.720345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":36,"alternative-id":["10.3389\/fphar.2021.720345"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.720345","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"article-number":"720345"}}